ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Ipsen, Debiopharm and AbbVie side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Ipsen×Debiopharm×AbbVie×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

IpsenDebiopharmAbbVie
studies on the registry358522,251
open to participants now256133
phase 3 studies under way16274
reach primary completion within a year16190
programswith a study of their own in two years9470+8 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseIpsenDebiopharmAbbVie
Phase 1

Ipsen: 1 of its 9 programs at phase 1

  1. tovorafenibphase 1
11%

Debiopharm: 1 of its 4 programs at phase 1

  1. DEBIO 1453Pphase 1
25%

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
Phase 244%

Debiopharm: 2 of its 4 programs at phase 2

  1. afabicinphase 2
  2. Anti-CD37/DM1 Derivative Antibody-drug Conjugate Debio 1562Mphase 2
50%

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
Phase 3

Ipsen: 4 of its 9 programs at phase 3

  1. corabotasephase 3
  2. elifibranorphase 3
  3. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3
  4. Palovarotenephase 3
44%

Debiopharm: 1 of its 4 programs at phase 3

  1. Octreotide Sustained-release Formulation Debio 4126phase 3
25%

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
Approved, new studies00%00%

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Ipsen3 readouts · 2 phase 3·

Ipsen, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. corabotasephase 3 · Dec 15 · NCT07435428
  2. elifibranorphase 3 · Dec 17 · NCT06730061
·········

Ipsen, Oct ’27: 1 program whose next study reaches primary completion

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3 · Oct 15 · NCT04243499
Debiopharm1 readouts · 0 phase 3·

Debiopharm, Dec ’26: 1 program whose next study reaches primary completion

  1. DEBIO 1453Pphase 1 · Dec 0 · NCT07035769
··········
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Ipsen

New programs 1

  • IPN60350phase 2 · first study · Nov 11 · Neoplasm Metastasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Debiopharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AbbVie

New programs 5

  • [11C]ABBV-112iearly phase 1 · first study · Nov 6
  • ABBV-7828phase 1 · first study · Sep 28
  • ABBV-1162phase 1 · first study · Sep 16
  • ABBV-253phase 1 · first study · Sep 1 · Carcinoma, Non-Small-Cell Lung
  • NOA LIFTphase 3 · first study · Aug 27

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 8 in all. A program counts in each condition its studies name most.

ConditionIpsenDebiopharmAbbVie
Leukemia, Myeloid, Acuteall three · compare here

Ipsen in Leukemia, Myeloid, Acute: 1 program

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3

Their studies: Ipsen’s studies of Leukemia, Myeloid, Acute in search

AbbVie in Leukemia, Myeloid, Acute: 2 programs

  1. pivekimab sunirinephase 3
  2. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Leukemia, Myeloid, Acute in search

Renal Insufficiencyall three · compare here

Ipsen in Renal Insufficiency: 1 program

  1. elifibranorphase 3

Their studies: Ipsen’s studies of Renal Insufficiency in search

Debiopharm in Renal Insufficiency: 1 program

  1. afabicinphase 2

Their studies: Debiopharm’s studies of Renal Insufficiency in search

AbbVie in Renal Insufficiency: 2 programs

  1. tavapadonphase 3
  2. emraclidinephase 2

Their studies: AbbVie’s studies of Renal Insufficiency in search

Migraine Disorders2 of 3 · compare here

Ipsen in Migraine Disorders: 1 program

  1. corabotasephase 3

Their studies: Ipsen’s studies of Migraine Disorders in search

–

AbbVie in Migraine Disorders: 4 programs

  1. MEDI0618phase 2
  2. botulinum toxin type Aapproved, new study
  3. atogepantapproved, new study
  4. ubrogepantapproved, new study

Their studies: AbbVie’s studies of Migraine Disorders in search

Dry Eye Syndromes2 of 3 · compare here

Ipsen in Dry Eye Syndromes: 1 program

  1. Palovarotenephase 3

Their studies: Ipsen’s studies of Dry Eye Syndromes in search

–
Cholangitis, Sclerosing2 of 3 · compare here

Ipsen in Cholangitis, Sclerosing: 1 program

  1. elifibranorphase 3

Their studies: Ipsen’s studies of Cholangitis, Sclerosing in search

–

AbbVie in Cholangitis, Sclerosing: 1 program

  1. vedolizumabphase 3

Their studies: AbbVie’s studies of Cholangitis, Sclerosing in search

Hematologic Neoplasms2 of 3 · compare here–

AbbVie in Hematologic Neoplasms: 1 program

  1. BTK Degrader ABBV-101phase 1

Their studies: AbbVie’s studies of Hematologic Neoplasms in search

Melanoma2 of 3 · compare here

Ipsen in Melanoma: 1 program

  1. tovorafenibphase 1

Their studies: Ipsen’s studies of Melanoma in search

–

AbbVie in Melanoma: 1 program

  1. vedolizumabphase 3

Their studies: AbbVie’s studies of Melanoma in search

Torticollis2 of 3 · compare here

Ipsen in Torticollis: 1 program

  1. corabotasephase 3

Their studies: Ipsen’s studies of Torticollis in search

–

AbbVie in Torticollis: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Torticollis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Ipsen 4 of 9 · Debiopharm 2 of 4 · AbbVie 54 of 70 programs (18 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AbbVie: 8).